CN113244374A - 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 - Google Patents

无精氨酸的tnfr:fc-融合多肽组合物及使用方法 Download PDF

Info

Publication number
CN113244374A
CN113244374A CN202110408576.1A CN202110408576A CN113244374A CN 113244374 A CN113244374 A CN 113244374A CN 202110408576 A CN202110408576 A CN 202110408576A CN 113244374 A CN113244374 A CN 113244374A
Authority
CN
China
Prior art keywords
composition
arginine
polypeptide
concentration
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110408576.1A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·马洛尼
宫克
罗伊·奥尔斯顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN113244374A publication Critical patent/CN113244374A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202110408576.1A 2011-07-01 2012-06-29 无精氨酸的tnfr:fc-融合多肽组合物及使用方法 Pending CN113244374A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504110P 2011-07-01 2011-07-01
US61/504,110 2011-07-01
CN201280032584.XA CN103930124B (zh) 2011-07-01 2012-06-29 无精氨酸的tnfr：fc-融合多肽组合物及使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280032584.XA Division CN103930124B (zh) 2011-07-01 2012-06-29 无精氨酸的tnfr：fc-融合多肽组合物及使用方法

Publications (1)

Publication Number Publication Date
CN113244374A true CN113244374A (zh) 2021-08-13

Family

ID=46579322

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110408576.1A Pending CN113244374A (zh) 2011-07-01 2012-06-29 无精氨酸的tnfr:fc-融合多肽组合物及使用方法
CN201280032584.XA Active CN103930124B (zh) 2011-07-01 2012-06-29 无精氨酸的tnfr：fc-融合多肽组合物及使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280032584.XA Active CN103930124B (zh) 2011-07-01 2012-06-29 无精氨酸的tnfr：fc-融合多肽组合物及使用方法

Country Status (13)

Country Link
US (2) US10995130B2 (cg-RX-API-DMAC7.html)
EP (1) EP2726090B1 (cg-RX-API-DMAC7.html)
JP (2) JP6463968B2 (cg-RX-API-DMAC7.html)
KR (1) KR102061355B1 (cg-RX-API-DMAC7.html)
CN (2) CN113244374A (cg-RX-API-DMAC7.html)
AU (2) AU2012279205B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013033671B1 (cg-RX-API-DMAC7.html)
CA (1) CA2840711C (cg-RX-API-DMAC7.html)
DK (1) DK2726090T3 (cg-RX-API-DMAC7.html)
EA (1) EA026226B1 (cg-RX-API-DMAC7.html)
MX (2) MX421100B (cg-RX-API-DMAC7.html)
WO (1) WO2013006454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400490B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
EP3569243A1 (en) 2011-06-28 2019-11-20 Inhibrx, LP Serpin fusion polypeptides and methods of use thereof
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
CN104010658A (zh) 2011-10-18 2014-08-27 科荣生生物科学公司 使用葡甲胺稳定的依那西普制剂
EP2869817A4 (en) * 2012-07-09 2016-04-06 Coherus Biosciences Inc STABLE AQUEOUS FORMULATIONS OF ETANERCEPT
CN104768576A (zh) 2012-09-07 2015-07-08 科荣生生物科学公司 稳定的阿达木单抗水性制剂
AU2013315750B9 (en) 2012-09-11 2018-11-15 Coherus Biosciences, Inc. Correctly folded etanercept in high purity and excellent yield
EP2926834A4 (en) * 2012-11-27 2016-04-20 Alteogen Inc COMPOSITION FOR STABILIZING A FUSION PROTEIN IN WHICH A PROTEIN AND A DOMAIN FC ARE MERGED
RU2663727C2 (ru) * 2013-05-02 2018-08-08 Мабксьенсе С.А. Альтернативные составы для химерных полипептидов tnfr:fc
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
ES2607489T3 (es) 2014-05-23 2017-03-31 Ares Trading S.A. Composición farmacéutica líquida
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
US9821059B2 (en) * 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
EP3236990B1 (en) 2014-12-22 2020-09-02 Ares Trading S.A. Liquid pharmaceutical composition
KR20240132521A (ko) * 2015-03-13 2024-09-03 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
CA3040899A1 (en) 2016-10-21 2018-04-26 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2018080196A2 (ko) * 2016-10-28 2018-05-03 (주)셀트리온 안정한 약제학적 제제
US11253569B2 (en) 2018-05-03 2022-02-22 Seattle Children's Hospital Methods of treating Kawasaki Disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
CN118510549A (zh) * 2021-09-22 2024-08-16 圣诺制药公司 具有减小的纳米颗粒尺寸和改善的多分散性指数的纳米颗粒药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
CN101217979A (zh) * 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂
EP1946776A1 (en) * 2002-02-27 2008-07-23 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
EP3192528A1 (en) * 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
KR100471843B1 (ko) 2002-06-11 2005-03-08 현대자동차주식회사 자동차의 아웃사이드 웨더스트립 장착구조
HUE051878T2 (hu) 2003-02-10 2021-03-29 Biogen Ma Inc Immunglobulin készítmény és annak elõállítási módszere
ATE394123T1 (de) 2003-02-28 2008-05-15 Ares Trading Sa Flüssige formulierungen des tumornekrosefraktor- bindungsproteins tbp-1
WO2005012353A1 (en) 2003-08-01 2005-02-10 Amgen Inc. Crystalline tumor necrosis factor receptor 2 polypeptides
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
MX2008013535A (es) * 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
TW200833357A (en) 2006-10-20 2008-08-16 Amgen Inc Stable polypeptide formulations
JP2010523695A (ja) * 2007-04-11 2010-07-15 アルコン リサーチ， リミテッド アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのＴＮＦαのインヒビターおよび抗ヒスタミン薬の使用
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
EP2598167B1 (en) * 2010-07-30 2015-04-01 Arecor Limited Stabilized aqueous antibody compositions
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072060A2 (en) * 2002-02-27 2003-09-04 Immunex Corporation Polypeptide formulation
EP1946776A1 (en) * 2002-02-27 2008-07-23 Immunex Corporation Stabilized TNFR-Fc composition comprising arginine
CN101217979A (zh) * 2005-06-14 2008-07-09 安姆根有限公司 自缓冲蛋白制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DOUGLAS L. MANN 等: "Effect of the Soluble TNF‐Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability", 《CLIN TRANSL SCI》, vol. 1, no. 12, 10 September 2008 (2008-09-10), pages 142 *
元英进: "《现代制药工艺学 上》", 31 July 2004, 北京：化学工业出版社, pages: 311 - 314 *
徐雄波: "多肽、蛋白质类药物微粒制剂的研究进展", 《广东药学院学报》, no. 6, 31 December 2007 (2007-12-31), pages 691 - 695 *

Also Published As

Publication number Publication date
EP2726090B1 (en) 2020-01-01
KR102061355B1 (ko) 2019-12-31
CN103930124B (zh) 2021-05-11
US11834491B2 (en) 2023-12-05
JP2014518276A (ja) 2014-07-28
MX358137B (es) 2018-08-06
BR112013033671B1 (pt) 2022-10-18
JP2017186349A (ja) 2017-10-12
NZ620160A (en) 2016-07-29
AU2017265026A1 (en) 2017-12-07
US10995130B2 (en) 2021-05-04
WO2013006454A1 (en) 2013-01-10
ZA201400490B (en) 2017-09-27
AU2012279205B2 (en) 2017-08-31
MX2018009524A (es) 2021-11-16
MX421100B (es) 2025-02-10
DK2726090T3 (da) 2020-01-20
CN103930124A (zh) 2014-07-16
EA201490195A1 (ru) 2014-04-30
EA026226B1 (ru) 2017-03-31
MX2014000093A (es) 2014-11-12
AU2017265026B2 (en) 2019-10-24
US20210309719A1 (en) 2021-10-07
JP6463968B2 (ja) 2019-02-06
EP2726090A1 (en) 2014-05-07
KR20140056218A (ko) 2014-05-09
CA2840711C (en) 2023-10-17
AU2012279205A1 (en) 2014-02-06
CA2840711A1 (en) 2013-01-10
US20140255400A1 (en) 2014-09-11
BR112013033671A2 (pt) 2017-01-24

Similar Documents

Publication Publication Date Title
US11834491B2 (en) Arginine-free TNFR:FC-fusion polypeptide compositions
US20220025016A1 (en) Compositions comprising a p75 tumor necrosis factor receptor/ig fusion protein
EP1946776B1 (en) Stabilized tnfr-fc composition comprising arginine
HK40057504A (en) Arginine-free tnfr:fc-fusion polypeptide compositions and methods of use
NZ620160B2 (en) Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40057504

Country of ref document: HK